Nanobac Earnings Yield from 2010 to 2024

NNBP Stock  USD 0.0001  0.00  0.00%   
Nanobac Pharmaceuticals Earnings Yield yearly trend continues to be relatively stable with very little volatility. Earnings Yield is likely to drop to -0.2. Earnings Yield is the inverse of the price-to-earnings ratio, representing the percentage of each dollar invested in the stock that was earned by the company. View All Fundamentals
 
Earnings Yield  
First Reported
2010-12-31
Previous Quarter
(0.19)
Current Value
(0.20)
Quarterly Volatility
0.01614027
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Nanobac Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nanobac Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 2.6 M or Total Revenue of 15.1 K, as well as many indicators such as Price To Sales Ratio of 90.9, Days Sales Outstanding of 56.52 or Invested Capital of 0.0. Nanobac financial statements analysis is a perfect complement when working with Nanobac Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Nanobac Pharmaceuticals Correlation against competitors.

Additional Tools for Nanobac Stock Analysis

When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.